Editas Medicine (EDIT) Liabilities and Shareholders Equity (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $186.5 million in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 45.39% year-over-year to $186.5 million in Q4 2025; TTM through Dec 2025 was $862.5 million, a 42.28% decrease from a year earlier, with the FY2025 full-year figure at $186.5 million, down 45.39% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $186.5 million, down from $201.8 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for EDIT reached as high as $780.3 million in Q1 2021 and fell as low as $186.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $477.3 million across 5 years, with a median of $501.9 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity soared 67.18% in 2021 and sank 45.39% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $677.5 million in 2021, then slipped by 24.08% to $514.3 million in 2022, then retreated by 2.95% to $499.2 million in 2023, then sank by 31.57% to $341.6 million in 2024, then sank by 45.39% to $186.5 million in 2025.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $186.5 million in Q4 2025, $201.8 million in Q3 2025, and $210.6 million in Q2 2025.